Rapid screening for sarcopenia

Morley, John E.; Cao, Li

doi:10.1002/jcsm.12079

Cited by 59 publications

(31 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35,40 This fact is exacerbated by the fact that no clinically validated biomarkers have been identified despite enormous research efforts both by academia and industry. 44 Despite this, there are still several definitions of sarcopenia with diverse cut-off values 45,46 that were all confirmed to be independent predictors of adverse outcomes. 34 In addition, a sarcopenia-specific Quality of Life questionnaire has recently been introduced.…”

Section: Chronic Heart Failure and Muscle Maintenancementioning

confidence: 99%

Skeletal muscle wasting in chronic heart failure

2018

View full text Add to dashboard Cite

Patients suffering from chronic heart failure (CHF) show an increased prevalence (~20% in elderly CHF patients) of loss of muscle mass and muscle function (i.e. sarcopenia) compared with healthy elderly people. Sarcopenia, which can also occur in obese patients, is considered a strong predictor of frailty, disability, and mortality in older persons and is present in 5–13% of elderly persons aged 60–70 years and up to 50% of all octogenarians. In a CHF study, sarcopenia was associated with lower strength, reduced peak oxygen consumption (peak VO2, 1173 ± 433 vs. 1622 ± 456 mL/min), and lower exercise time (7.7 ± 3.8 vs. 10.22 ± 3.0 min, both P < 0.001). Unfortunately, there are only very limited therapy options. Currently, the main intervention remains resistance exercise. Specialized nutritional support may aid the effects of resistance training. Testosterone has significant positive effects on muscle mass and function, and low endogenous testosterone has been described as an independent risk factor in CHF in a study with 618 men (hazard ratio 0.929, P = 0.042). However, the use of testosterone is controversial because of possible side effects. Selective androgen receptor modulators have been developed to overcome these side effects but are not yet available on the market. Further investigational drugs include growth hormone, insulin‐like growth factor 1, and several compounds that target the myostatin pathway. The continuing development of new treatment strategies and compounds for sarcopenia, muscle wasting regardless of CHF, and cardiac cachexia makes this a stimulating research area.

show abstract

Section: Chronic Heart Failure and Muscle Maintenancementioning

confidence: 99%

Skeletal muscle wasting in chronic heart failure

2018

View full text Add to dashboard Cite

show abstract

“…Already a number of approaches have been developed to increase awareness of these syndromes (55,56). These approaches include the Kihon Index (57, 58), EasyCare (59, 60), Vulnerable Elder Survey (61), the Gerontopole Frailty Index (62)(63)(64)(65), and the Rapid Geriatric Assessment (66,67).…”

Section: Modern Geriatric Giantsmentioning

confidence: 99%

Geriatrics in the 21st century

Vellas

Morley

2018

The Journal of nutrition, health and aging

Self Cite

View full text Add to dashboard Cite

“…These clinics are usually called 'Diabetic Foot Clinics' or 'High Risk Foot Clinics' depending on whether diabetes is a criterion for patient inclusion. The SARC-F questionnaire was originally developed as a screening test for sarcopenia [6]. Dysvascular foot disease is associated with disability and reduced quality of life on a number of validated tools for measuring quality of life such as SF-36 and NeuroQol [4], [5].…”

Section: Introductionmentioning

confidence: 99%

The association between SARC‐F status and quality of life in High Risk Foot Clinic patients

Churilov

Чурилов

Proctor

et al. 2019

JCSM Clinical Reports

View full text Add to dashboard Cite

Background High Risk Foot Clinic (HRFC) patients have foot ulceration commonly associated with poorer quality of life (QoL). A positive SARC-F test is predictive of sarcopenia. The objective of this study is to investigate whether SARC-F positive status is associated with lower QoL among attendees of HRFC, which is currently unknown. Methods and resultsIn this cross-sectional study ambulatory HRFC patients were recruited at metropolitan tertiary referral hospital over one year. Demographics, comorbidities, SARC-F and EQ-5D-3L (EuroQol Group) outcomes were collected. Association between SARC-F status and EQ-5D visual analogue scale measurement, as well as individual EQ-5D-3L dimensions were investigated using, respectively, linear robust and ordinal logistic regression modelling. The clinic was attended by 122 new patients, 85 of whom (69%) completed the questionnaires with no selection bias identified. 43/85 (51%) patients were SARC-F positive as indicated by a score of 4 or greater. No significant differences between SARC-F positive and negative patients were identified in age or diabetes status. SARC-F positive patients had consistently lower EQ-5D-3L visual analogue scale measurement [mean 5.3 (SD 2.0); median 5 (IQR: 4, 6.5)] compared to SARC-F negative patients [6.6 (SD 1.9); 7 (5.5, 7.5)], adjusted mean difference -1.2 (95%CI: -2.1, -0.4; p=0.007). SARC-F positive patients demonstrated consistent and statistically significantly worse EQ-5D-3L scores on mobility, personal care and usual activities, but not on anxiety/depression and pain/discomfort components. Conclusions Approximately half of HRFC patients are SARC-F positive and exhibit significantly lower QoL as measured by EQ-5D-3L compared to SARC-F negative patients.

show abstract

Rapid screening for sarcopenia

Cited by 59 publications

References 61 publications

Skeletal muscle wasting in chronic heart failure

Skeletal muscle wasting in chronic heart failure

Geriatrics in the 21st century

The association between SARC‐F status and quality of life in High Risk Foot Clinic patients

Contact Info

Product

Resources

About